Healthcare sector | Medical Devices industry
| Price | $2.08 |
|---|---|
| Shares Outstanding | 3.02M |
| All-Time Low | $1.36 |
| 52-Week Low | $2.11 |
| Net Cash / Share | $0.31 |
|---|---|
| Net Current Assets / Share | $1.19 |
| Net Tangible Assets / Share | $1.4 |
| Shares Outstanding Ave Change (Annual) | 16.54% |
| Shares Δ YoY | 21.09% |
| Avg CA Burn (Annual %) | -13.59% (as of 2-20-2026) |
| Avg CA Burn (Quarterly %) | -2.01% (as of 2-20-2026) |
| Max Earning Power / Share | $-4.0 |
|---|---|
| Adjusted Earning Power |
$-4.16
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
1.66%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 0 (as of 2-20-2026) |
| Avg EBITDA (5Q) | 0 (as of 2-20-2026) |
| Avg Net Income (5Y) | -5.7M (as of 2-20-2026) |
| Avg Net Income (5Q) | -995K (as of 2-20-2026) |
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 2-20-2026 |
| Consecutive Years Paid | No | 2-20-2026 |
| Pays Dividend | No | 2-20-2026 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | No | 2-20-2026 |
| Net Income Positive | No | 2-20-2026 |
| Current Dividend Streak | No | 2-20-2026 |
Pick a metric to view its history table and chart.
Formula: Tangible Book Value / shares from balance statements. Includes 5 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-11-30 | Quarterly | $1.43 | 4.2M ($4,216,000) | 2.9M (2,947,966) |
| 2025-08-31 | Quarterly | $1.75 | 4.9M ($4,932,000) | 2.8M (2,815,410) |
| 2025-05-31 | Quarterly | $1.52 | 3.9M ($3,877,000) | 2.5M (2,546,216) |
| 2025-05-31 | Annual | $1.52 | 3.9M ($3,877,000) | 2.5M (2,546,216) |
| 2025-02-28 | Quarterly | $2.08 | 5.3M ($5,300,000) | 2.5M (2,545,750) |
| 2024-11-30 | Quarterly | $2.13 | 4.9M ($4,878,000) | 2.3M (2,292,124) |
| 2024-05-31 | Annual | $3.03 | 6.4M ($6,379,000) | 2.1M (2,102,705) |
| 2023-05-31 | Annual | $5.50 | 11.6M ($11,559,000) | 2.1M (2,102,705) |
| 2022-05-31 | Annual | $5.07 | 8.2M ($8,155,000) | 1.6M (1,608,490) |
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2025-05-31 | 5.3M ($5,311,000) |
| 2024-05-31 | 5.4M ($5,415,000) |
| 2023-05-31 | 5.3M ($5,339,000) |
| 2022-05-31 | 18.9M ($18,871,000) |
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| No dividend payment history available yet | |
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2026-01-16 | 3,020,067 | +72,101 |
Latest short-interest change: 72,362 shares (2.71% of float) | Days to cover: 5.20
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-02-27 | 72,362 shares | -1,995 | -2.68% |
| 2026-02-11 | 74,357 shares | -13,837 | -15.69% |
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| No interesting volume events | ||||
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.